C.G.M.3 Ltd is an early-stage medical company that was founded in 2007 and joined
NAIOT Venture Accelerator, at Yokneam, Israel in 2009, as a seed company.
C.G.M.3 Ltd is developing a miniaturized implantable device which utilizes a
groundbreaking solution for reliable, real- time, long-term Continuous Glucose
Monitoring (CGM).
The device will ultimately offer a true resolution and improved quality of life for
diabetes patients. In fact, C.G.M.3 solution presents the missing link towards a potent
closed –loop artificial pancreas.

MORRIS C. LASTER, MD

Dr. Laster is a healthcare entrepreneur with over 14 years of experience in the
biopharmaceutical industry. He previously founded four publicly traded companies
including Keryx (simultaneous listing on NASDAQ: KERX; and AIM: KRX)), XTL (LSE:
XTL) and Neose Technologies (NASDAQ: NTEC). During his time at Keryx,

Dr. Laster was instrumental in changing FDA policy by securing a Subpart H
accelerated approval strategy for diabetic nephropathy.
Dr. Laster received his MD from Downstate Medical Center in New York and
performed post graduate work in surgery at Case Western Reserve University
Hospital in Ohio

MOSHE PHILLIP, MD

Professor Phillip is the Director of the Institute for Endocrinology and Diabetes, Israel
National Center for Childhood Diabetes and servedas the Vice Dean and Head of
School for Continuing Medical Education of the Sackler School of Medical Education
at Tel Aviv University.
Professor Phillip manages the Institute’s Clinical Research Center (CRC), with in
house research coordinators, statisticians, nurses and physicians.
Professor Phillip is the senior PI of numerous clinical studies including Growth
hormone (norditropin), Lantus (Sanofi Aventis), Detemir (Novo Nordisk),
Candersartan Cilexetil (Astra Zeneca), and Medtronic’s patented insulin pump and
glucose sensors.
Professor Phillip's expertise and experience in both bench and clinical research
includes clinical studies from Phase II to post marketing.
His bench research is focused mainly on finding ways to prevent diabetic
complications and understanding the interaction between hormones and the
epiphyseal growth plate, while his clinical research focuses on diabetes and growth,
including studies in immunomodulation and prevention of diabetes mellitus. Professor
Phillip is an Associate Editor and on the editorial board of 3 medical journals and a
member of the Pediatric and Diabetic National Councils of Health.

Naiot is a Venture Accelerator part of Ofer Hi-Tech Group. Ofer Hi Tech Group is a
leading investor in technology-based Israeli-related companies, from pre-seed
through early-stage to publicly-traded, working in communications, software, medical
devices, bio-technology and microelectronics.
Please find us on Naiot portfolio in the web: www.naiot.com

Yinnon Elisha,   C.E.O   C.G.M.3 Ltd
New industrial Park, P.O.Box 620
Yokneam 20692, Israel
Tel: +972. 4. 909. 0000
Fax: +972. 4. 909. 0001
E-mail: yinnon@cgm-3.com